What is the PBE ETF? - Returns, Expense Ratio, Holdings & Alternative ETFs Complete Guide
The Invesco Biotechnology & Genome ETF (PBE) uses a momentum- and quality-factor Intellidex index to screen innovative healthcare names. The key selection criteria are its strategy and fee differences from the broad healthcare ETF XLV and biotech ETFs XBI and IBB, and it's worth checking the dividend and outlook together.
SubscribeWhat is the Invesco Biotechnology & Genome ETF?
It is a sector-themed ETF that tracks the Dynamic Biotech & Genome Intellidex Index. It includes U.S.-listed biotechnology and genomics-related companies selected through multi-factor criteria.
It is suitable for investors who want concentrated exposure to innovative drug development and genomics themes within healthcare and are willing to tolerate sector volatility.
The ETF is managed by Invesco using a passive (index-tracking) approach.
How to Invest in the Invesco Biotechnology & Genome ETF
| Item | Details |
|---|---|
| Tracking Index | Dynamic Biotech & Genome Intellidex |
| Management Style | Passive (factor-based index tracking) |
| Rebalancing Frequency | Quarterly |
| Dividend Schedule | Irregular / Small amounts |
| Fund Manager | Invesco |
| Total Expense Ratio | 0.59% |
It selects and includes U.S. biotech and genome stocks based on multiple investment appeal criteria such as price momentum, earnings momentum, quality, management activity, and valuation. It uses a rules-based approach that balances large-, mid-, and small-cap names for diversification, with rebalancing applied quarterly in accordance with the index rules.
- Multi-factor Intellidex rules-based stock selection
- Balanced diversification across large-, mid-, and small-caps
Invesco Biotechnology & Genome ETF Size and Costs (AUM · Expense Ratio)
Assets under management (AUM) stand at $430.9M, and the total expense ratio is 0.59% annually.
Because it focuses on the biotech and genome theme compared with broad healthcare ETFs, volatility tends to be higher, while offering differentiated exposure driven by its selection rules.
Invesco Biotechnology & Genome ETF Performance and Fund Flows
1-Year Price Performance
Dividend & Yield
52-Week Price RangeDriven by the characteristics of the biotech sector, performance has shown high volatility based on clinical trial outcomes, regulatory developments, and the interest-rate environment. Moves tend to be wider than those of the broader market, so short-term trends are highly sensitive to thematic sentiment.
Fund flows fluctuate based on investor interest in innovative drug development and genomics themes, with capital flowing into growth themes during risk-on phases. Conversely, when interest-rate pressures mount, capital can rotate out of high-growth biotech names.
Invescos Biotechnology & Genome ETF Strengths and Weaknesses
The strengths are rules-based diversification with concentrated exposure to innovative healthcare themes, while the weakness is the high volatility stemming from sector concentration.
💪 Key Strengths
⚠️ Points to Watch
Invesco Biotechnology & Genome ETF Alternatives and Related Products
The comparison ETFs shown in the table span different categories such as financials, industrials, and Nasdaq, so differences in expense ratio, provider, and strategy are significant. Within the same healthcare theme, more direct alternatives include the broad healthcare sector ETF XLV, the equal-weight biotech ETF XBI, and the market-cap-weighted biotech ETF IBB. For even greater focus on genomics and genetic engineering, ARKG is also worth considering.
Peer Comparison ETFs| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
 VFH | Vanguard Financials ETF | $136.04 | +0.5% | $13.2B | 0.09% | 1.73% | +5.9% |
 ONEQ | Fidelity Nasdaq Composite Index ETF | $105.23 | +1.1% | $10.8B | 0.21% | 0.49% | +16.5% |
 VIS | Vanguard Industrials ETF | $321.89 | +0.9% | $7.7B | 0.09% | 0.95% | +7.6% |
 FV | First Trust Dorsey Wright Focus 5 ETF | $75.11 | +0.8% | $3.9B | 0.89% | 0.35% | +20.2% |
 IYF | iShares U.S. Financials ETF | $130.28 | +0.6% | $3.8B | 0.37% | 1.49% | +6.4% |
Top Holdings| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
 UTHR | United Therapeutics Corp | 0.06% | $563.49 | +1.7% | $24.2B | 20.2 | - |
| REGN | Regeneron Pharmaceuticals Inc | 0.05% | $805.67 | -0.2% | $82.9B | 19.9 | 0.44% |
| ILMN | Illumina Inc | 0.05% | $282.86 | +5.6% | $42.7B | 52.7 | - |
| AMGN | AMGEN Inc | 0.05% | $438.34 | -0.1% | $237.0B | 27.2 | 2.31% |
| BIIB | Biogen Inc | 0.05% | $240.98 | -0.9% | $35.6B | 42.7 | - |
 CDNA | Caredx Inc | 0.05% | $70.74 | +2.2% | $3.7B | 34.1 | - |
| VRTX | Vertex Pharmaceuticals Inc | 0.05% | $524.52 | +1.9% | $132.9B | 30.5 | - |
| RPRX | Royalty Pharma plc | 0.05% | $62.15 | -0.2% | $35.7B | 33.1 | 1.65% |
 INCY | Incyte Corp | 0.05% | $113.44 | -2.7% | $23.0B | 14.5 | - |
| ALNY | Alnylam Pharmaceuticals Inc | 0.05% | $225.10 | -2.4% | $30.1B | 38.0 | - |
Investor Checklist for the Invesco Biotechnology & Genome ETF
Here are the points to review before investing in PBE. As a thematic ETF, its volatility, cost, and selection methodology differ from broad core ETFs, so these need to be verified in advance.
| Checkpoint | What to Confirm | Current Status |
|---|---|---|
| 💵 Expense Ratio | Check cost level relative to thematic ETF peers | Somewhat higher than category average |
| 📊 Sector Concentration | Exposure to a single biotech sector | High concentration |
| 🧬 Selection Method | Understand the Intellidex rules-based approach | Rules-based selection |
| 💱 FX | Impact on KRW-converted returns | No currency hedging |
Concentration in a single biotech sector along with clinical and regulatory events are the main drivers of short-term volatility. Even when the broader market is stable, the fund can swing sharply on its own based on thematic sentiment.
It is a fitting choice for investors seeking concentrated exposure to the innovative biotech and genomics theme. If broad healthcare diversification is the priority, XLV is recommended; for a more aggressive biotech bet, XBI and IBB are also worth comparing side by side.
SubscribeDisclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 11, 2026.
Today's 5 AI picks, all free